An active ingredient in eye drops that were being developed for the treatment of a form of eye disease has shown promise for treating an aggressive form of blood cancer. Scientists have found that this compound, which targets an essential cancer gene, could kill leukemia cells without harming non-leukemic blood cells. The results reveal a potential new treatment approach for an aggressive blood cancer with a poor prognosis.